Altered metabolism is one of the hallmarks of cancer cells. Pentose phosphate pathway (PPP) is a fundamental component of cellular metabolism. Glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, is elevated in many cancers and contributes to tumor growth by producing ribose-5-phosphate and NADPH through PPP. However, the role of G6PD in hepatocellular carcinoma (HCC) metastasis and the clinical significance of G6PD in HCC progression and prognosis have not been well determined. In this study, by investigating tissue samples from HCC patients and HCC cell lines, we found that elevated G6PD expression is significantly associated with HCC metastasis and poor prognosis of HCCs, and that knockdown of G6PD inhibits in vitro proliferation, migration and invasion of HCC cell lines. Further studies reveal that G6PD contributes to HCC migration and invasion of hepatocellular carcinoma cells by inducing epithelialmesenchymal transition through activation of signal transducer and activator of transcription 3 (STAT3) pathway. Our findings suggest that targeting G6PD could open up possibilities for metastasis intervention and improve the patients' outcomes for HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide [1] . Until recently, surgical resection, liver transplantation, and local ablation are main curative therapies. Unfortunately, these therapies are only effective to one-third of HCC patients. For most patients with advanced-stage carcinomas, few effective treatments are available [2, 3] .
As many other tumors, HCCs are known to undergo metabolic alterations to sustain faster proliferation [4] . Improved understanding of these metabolic alternations in HCC would help to optimize prevention, early diagnosis and treatment of HCC. It is well known that cancer cells consume a large amount of glucose, maintain high rate of glycolysis and convert a majority of glucose into lactic acid even in the presence of oxygen compared to that of normal cells [5] . In addition, cancer cells exhibit alterations in several energy metabolism pathways including tricarboxylic acid (TCA) cycle, glutaminolysis, mitochondrial respiratory chain oxidative phosphorylation, and pentose phosphate pathway (PPP) [6] .
PPP is a fundamental component of cellular metabolism, and is important to maintain carbon homeostasis, to provide precursors for nucleotide and amino acid biosynthesis, to provide reducing molecules for anabolism, and to defeat oxidative stress [7] . Activation of PPP could contribute to many of the unique metabolic requirements of tumor cells by producing ribose-5-phosphate and nicotinamide adenine dinucleotide phosphate (NADPH) which are required for macromolecular biosynthesis and cell growth [8, 9] . The PPP is composed of the oxidative and nonoxidative arms. Glucose-6-phosphate dehydrogenase (G6PD), the first enzyme in the oxidative arm of PPP, is the ratelimiting enzyme of the PPP [9] . Elevated expression and activity of G6PD are observed in many cancers including leukemia, gastric cancer, renal cell carcinomas, and HCC [10] [11] [12] [13] . However, the role of G6PD in HCC metastasis and the clinical significance of G6PD in HCC progression and prognosis have not been well determined.
The epithelial to mesenchymal transition (EMT), first noted during embryogenesis and adult tissue repair and maintenance, plays an important role in tumor cell invasion and metastasis [14] . Twist is one of the important transcriptional factors involved in EMT, and it can inhibit E-cadherin expression, up-regulate N-cadherin expression, and initiate EMT [15] . The signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family (STAT1, 2, 3, 4, 5α, 5β, and 6) of latent, cytosolic transcription factors that directly relate signals from the plasma membrane to the nucleus, and is implicated as an inducer of EMT and cancer metastasis [16, 17] . STAT3 has been shown to directly bind to Twist1 promoter and upregulate Twist1 expression [18] . Interestingly, it has been reported that variant G6PD levels can regulate the expression of STAT3 and phospho-STAT3 in human melanoma cells [19] .
In this study, we examined the expression of G6PD in tissue samples from HCC patients and HCC cell lines, and revealed the role and the mechanism of elevated G6PD expression in HCC metastasis.
Materials and Methods

Patients and clinical samples
The samples of metastatic-free HCCs (defined as without metastatic clinical manifestation and image features during 5-year follow-up after curative resection) and extrahepatic metastatic HCCs (defined as classic image features or pathologic diagnosis appeared within 2-year followup after curative resection) were obtained from Department of General Surgery, Huashan Hospital, Fudan University (Shanghai, China). Clinical samples were collected from patients after obtaining informed consent in accordance with a protocol approved by the Ethics Committee of Fudan University.
Another independent cohort of HCC samples (n = 127) was obtained from patients who had undergone curative hepatectomy at Qidong People's Hospital (Qidong, China) during the year [2005] [2006] [2007] [2008] [2009] . None of the patients in our study received radiotherapy or chemotherapy before surgery, and every patient was followed until June 2016. Follow-up procedures were described in our previous study [20] . Briefly, patients were monitored by serum α-fetoprotein (AFP), abdominal ultrasonography and chest radiography with an interval of 2-6 months according to the postoperative time. Enhancement computed tomography scanning or magnetic resonance imaging was performed every 6-12 months or suspicious recurrence. Combined treatment modalities after recurrence were administered according to a uniform guideline. Overall survival (OS) was defined as the interval between surgery and either death or the last observation taken. Progression-free survival (PFS) was defined as the interval between surgery and disease recurrence or progression. If recurrence was not diagnosed, patients were censored on the date of death or the last follow-up. Clinical samples were collected from patients after obtaining informed consent in accordance with a protocol approved by the Ethics Committee of Qidong People's Hospital.
Tissue microarray and immunohistochemistry
Construction of tissue microarray (TMA) and protocols of immunohistochemistry have been described previously [21] . TMA blocks were cut into 4 μm in thickness and mounted onto 3-aminopropyltrioxysilanecoated slides, dewaxed and blocked in hydrogen peroxide/methanol solution. Antigen retrieval was performed by pressure-cooking the sample in 0.08% citrate buffer for 20 min. Primary antibody against G6PD (1:200) was purchased from Sigma (St Louis, USA). Before it was used on the arrays, the antibody was tittered against normal control tissues to determine the dilution that rendered optimal sensitivity and specificity. Staining results were visualized by sequential incubations of TMAs with the components of the Envision-plus detection system (EnVision +/HRP/Mo, Dako, Glostrup, DK) and 3,3′-diaminobenidine. Negative controls were treated in the same way without adding the primary antibody. Immunohistochemistry staining was assessed by two independent pathologists with no prior knowledge of patient characteristics. Discrepancies were resolved by consensus. The staining extent score was on a scale of 0 to 3, corresponding to the percentage of immunoreactive tumor cells and the staining intensity.
Cell culture
Six human HCC cell lines with various metastatic potentials (HepG2, PLC, Huh7, MHCC97L, MHCC97H, and HCCLM3), and one human non-transformed hepatic cell line, L02, were used in this study. MHCC97H and HCCLM3 were established from the same parent human HCC cell line MHCC97. They have a genetically identical background and stepwise increasing metastatic potentials. HepG2 and PLC cells were obtained from American Type Culture Collection (Rockville, USA). Huh7 and L02 cells were obtained from Shanghai Cell Bank of Chinese Academy of Science (Shanghai, China). Cells were maintained in DMEM (Gibco, NewYork, USA) supplemented with 10% (v/v) FBS at 37°C in 5% CO 2 .
Materials and plasmids
Stattic and oxaliplatin were purchased from Selleck (Houston, USA). G6PD lentiviral overexpression vector was obtained by cloning G6PD cDNA sequence into pCDH vector (System Biosciences, Palo Alto, USA). RNAi insensitive G6PD was made by performing site-directed mutagenesis to introduce five silent mutations against G6PD RNAi-2 shRNA, primer sequences were as follows: F: 5′-TTT GGCACTGAGGGTCGCGGGGGATACTTTGACGAGTTTGGGA TCATCCGGGACGTGAT-3′ and R: 5′-ATCACGTCCCGGATGAT CCCAAACTCGTCAAAGTATCCCCCGCGACCCTCAGTGCCAAA-3′.
Quantitive RT-PCR
Total RNA was freshly prepared using the Absolutely RNA ® RNA Miniprep Kit (Stratagene, La Jolla, USA). An aliquot of the total RNA was reverse-transcribed to obtain cDNAs. Quantitative RT-PCR was conducted on an ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Carlsbad, USA) using a hot-start SYBR-green-based method followed by melting curve analysis to verify specificity of the products. The Ct value (cycle number at threshold) was used to calculate the relative amount of mRNA. The Ct value of each determined RNA sample was normalized by subtracting that of control GAPDH RNA to obtain the ΔCt value, and the relative mRNA level was calculated as 2 −ΔCt . Primer sets for quantitative RT-PCR were listed in Table 1 .
Western blot analysis
Total protein was extracted by lysing cells in radio immunoprecipitation assay (RIPA) buffer containing protease inhibitor. Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membranes. After being blocked with 5% non-fat milk in TBST, membranes were incubated with the primary antibody. Antibodies against G6PD (Sigma), STAT3 (Santa Cruz, Santa Cruz, USA), Phospho-STAT3 (Tyr-705) (Santa Cruz), MMP-2 (Cell Signaling Technology, Danvers, USA), MMP-9 (Abcam, Cambridge, USA), Twist (GeneTex, Hsinchu City, China), E-cadherin (Cell Signaling Technology), N-cadherin (Cell Signaling Technology) were used. Goat-anti-rabbit IgG conjugated to horseradish peroxidase (Cwbiotech, Shanghai, China) was used as the secondary antibody. Protein was detected with Image Acquisition using ImageQuant™ LAS 4000 (GE, Bethesda, USA).
Lentivirus-mediated knockdown of G6PD expression
The design of short hairpin RNAs (shRNAs) was assisted by the web-based software provided by Life Technologies (Gaithersburg, USA, http://rnaidesigner.invitrogen.com/rnaiexpress/). The G6PD RNAi-2 shRNA targeting sequence is 5′-GGGCTATTTCGATGAA TTTGG-3′, the G6PD RNAi-3 shRNA targeting sequence is 5′-AA CTCAGATGACGTCCGTGAT-3′, and the control shRNA sequence is 5′-CCGCAGGTATGCACGCGT-3′. Blast searches were performed using the National Center for Biotechnology Information expressed sequence tag database to ensure that the shRNA only targets human G6PD mRNA. The pLKO.1-TRC cloning vector system (Addgene, Cambridge, USA) was utilized to produce lentivirus. Control lentivirus encoding scramble shRNA and lentivirus encoding shRNA targeting G6PD were produced according to the manufacturer's instructions. MHCC97H or HCCLM3 cells were infected with these lentiviruses for 24 h, and then control RNAi, G6PD RNAi-2, and G6PD RNAi-3 stable cell lines were obtained by puromycin selection for 1 week.
G6PD activity assay
Briefly, cells were rapidly homogenized in equivalent volumes of ice cold PBS, and centrifuge to collect the cell lysates. The cell lysates were subjected to determine cellular G6PD activity by G6PD Assay Kit (Sigma) according to the manufacturer's instructions.
Cell proliferation assay and colony formation assay
Different cell lines were first plated on 96-well plates overnight for cell adherence, and were maintained at 37°C, 5% CO 2 for another 96 h. Cell number were determined using CCK8 kit according to the manufacturer's instructions. For colony formation assay, cells were seeded for colony formation in 6-well plates at 500 cells per well. After 14-21 days, colonies were stained by crystal violet (Sigma).
Each assay was performed in triplicate on two independent occasions.
In vitro migration and invasion assays
The migration ability of HCC cells was determined by wound healing assays. Cells were seeded in 24-well plates. The cell layer was scratched with the tip of a 200-μl pipette. The wound width was measured at 24 and 48 h after scratching in order to evaluate the wound healing ability of tested cells. The invasive ability of HCC cells was determined using 24-well transwell chambers coated with matrigel (BD, San Jose, USA). Chambers have upper and lower culture compartments that are separated by polycarbonate membranes with 8 μm pores (Costar, Cambridge, USA). The bottom chamber was filled with DMEM containing 10% FBS as a chemoattractant. Cells in serum-free medium were seeded at 5 × 10 4 in the top chamber and incubated at 37°C in a humidified incubator containing 5% CO 2 . Cells that migrated to the underside of the membrane were stained with Giemsa solution (Sigma), imaged, and counted with a microscope (Leica, Wetzlar, Germany). All experiments were performed in triplicate.
Statistical analysis
Data are expressed as the mean ± standard deviation (SD). Statistical analysis was performed with SPSS version 15.0 (SPSS Inc., Chicago, USA). Experimental differences were analyzed as indicated in figure legends. P < 0.05 were considered statistically significant. 
Results
Elevated G6PD expression is correlated with HCC metastasis
To investigate the role of G6PD in HCC metastasis, we first analyzed the expression of G6PD and the other two enzymes in the oxidative arm of PPP by quantitative RT-PCR in 30 paired samples of HCC and adjacent non-tumorous tissues from HCC patients. The expression of G6PD was up-regulated in HCC tissues versus adjacent non-tumorous liver tissues (P < 0.001), while the expression of 6-phosphogluconolactonase (6PGL) and 6-phosphogluconate dehydrogenase (6PGD) genes were not affected (Fig. 1A) . Furthermore, in comparison to non-metastatic HCC tissues, G6PD mRNA levels were significantly higher (P < 0.01) in metastatic HCC tissues (Fig. 1B) . We also analyzed the expression of G6PD in a panel of human HCC cell lines with different metastatic potentials [22] . The G6PD mRNA and protein levels were both significantly up-regulated in six established HCC cell lines compared with the non-transformed hepatic cell line L02 (Fig. 1C,D) . Moreover, the expression levels of G6PD in the metastatic HCC cell lines MHCC97L, MHCC97H, and HCCLM3 were much higher than those in the HCC cell lines without metastatic potential, including Huh7, PLC, and HepG2 (Fig. 1C,D) .
To further validate the association of G6PD expression with HCC metastasis, we next analyzed protein expression levels based on immunohistochemistry (IHC) analysis in another 43 paired HCC patients with or without extrahepatic metastasis. As shown in Fig. 2A-C , representative images of G6PD expression in extrahepatic metastasis HCC (EHMH, including lung, adrenal, lymph node, and omentum metastasis) and metastasis-free HCC (MFH) exhibited a higher G6PD protein level in EHMH than that in MFH. These results indicate that significant up-regulation of G6PD expression occurs in HCC and correlates with HCC metastasis.
Association of G6PD expression with outcomes of HCC patients
To further investigate the association of G6PD with metastasis as well as the prognostic value of G6PD in HCCs, tissue microarray based immunohistochemistry (IHC) study of G6PD in another independent 127 HCC patients from the same institute with complete follow-up data was performed. These patients were divided into high (score 2-3) or low (score 0-1) G6PD expression groups according to the immunostaining scores (Fig. 2B) . G6PD expression was Figure 1 . G6PD is elevated in HCC and correlated with HCC metastasis (A) Quantitative RT-PCR analysis of mRNA levels for genes involved in the pentose phosphate pathway in 30 paired samples of human HCC tissues and adjacent nontumor tissues. (B) Quantitative RT-PCR analysis of G6PD mRNA levels in metastatic and non-metastatic HCC tissues. Statistical analysis was performed with ratio t-test; data are shown as the mean±SD after log transformation (n = 30). Each dot represents the mean of relative mRNA levels (log 10 ) for the indicated gene from experiments in triplicate in each tissue sample. (C, D) Quantitative RT-PCR analysis of G6PD mRNA levels (C) and immunoblots of G6PD protein (D) in HCC cell lines with different metastatic potentials and the non-transformed hepatic cell line L02. **P < 0.01, ***P < 0.001. detected exclusively in the cytosol with granular pattern. Survival analysis showed that high expression of G6PD (score 2 and score 3) is significantly correlated with reduced overall survival (OS) (Fig. 2D , P < 0.001) and disease-free survival (DFS) (Fig. 2E , P < 0.001) compared with patients with low G6PD protein levels (score 0 and score 1). These data indicate that elevated G6PD expression is significantly associated with poor prognosis of HCCs.
Knockdown of G6PD inhibits in vitro proliferation, migration and invasion of HCC cell lines
To understand the role of G6PD in HCC metastasis, we knocked down G6PD expression by using RNAi approach in MHCC97H and HCCLM3 cells, which have high metastatic potential and high endogenous G6PD expression (Fig. 1C,D) . The expression of G6PD was verified by western blot analysis (Fig. 3A) and G6PD activity assay (Fig. 3B) . G6PD knockdown resulted in a significant suppression of cell proliferation and colony formation in MHCC97H and HCCLM3 cells (Fig. 3C,D) . Next, the effects of G6PD knockdown on cell migration and invasion were examined. Mobility of MHCC97H and HCCLM3 cells in wound healing assays was significantly decreased after knockdown of G6PD (Fig. 4A,B) . Similarly, in matrigel cell invasion assays, knockdown of G6PD significantly decreased migration of MHCC97H and HCCLM3 cells (Fig. 4C) . These results indicate that knockdown of G6PD inhibits in vitro proliferation, migration and invasion of HCC cell lines.
Knockdown of G6PD shifts EMT status in HCC cells
To explore the mechanism of suppressing cell migration and invasion by knockdown of G6PD, we examined the effect of knockdown of G6PD on the expression of EMT-related genes and metastasis-related genes in MHCC97H and HCCLM3 cells. Interestingly, Twist, the important transcriptional factor in EMT, was significantly downregulated after knockdown of G6PD (Fig. 5A,B) , suggesting that knockdown of G6PD can inhibit EMT in MHCC97H cells. We then examined the effect of G6PD knockdown on expression of EMTrelated factors. As we expected, after knockdown of G6PD, the protein and mRNA levels of E-cadherin were significantly increased, whereas that of N-cadherin were significantly reduced (Fig. 5A,B) . Similar results were obtained by using HCCLM3 cells (Fig. 5C,D) . Furthermore, the expression of metastasis-related genes, MMP-2 and MMP-9, were also decreased after knockdown of G6PD in MHCC97H and HCCLM3 cells (Fig. 5) . The above results indicate that knockdown of G6PD shifts EMT status in HCC cells.
G6PD promotes EMT by activation of STAT3 pathway
Twist, MMP-2, MMP-9 are known to be STAT3 target genes [17] . Previous studies have also shown that the expression of STAT3 can be regulated by G6PD expression in human melanoma cells [19, 23] . Therefore, we hypothesize that G6PD regulates EMT-related genes by activation of STAT3 pathway in HCC cells. Firstly, we examined the effect of G6PD knockdown on the expression of STAT3 and (Fig. 6A,B) . As STAT proteins, particularly STAT3 and STAT5, are constitutively activated in a large number of human cancers [24] , we also examined the effect on STAT5, and found that G6PD knockdown had no effect on the expression of phospho-STAT5 and STAT5 in MHCC97H cells (Fig. 6A,B) . To further validate whether G6PD could promote EMT by activating STAT3 pathway in HCC cells, we overexpressed G6PD with engineered cDNA that was not sensitive to shRNA into the Figure 4 . Knockdown of G6PD inhibits migration and invasion of HCC cell lines (A,B) The effects of G6PD knockdown on migration of MHCC97H and HCCLM3 cells by wound healing assay. The wound closure was quantified at 0, 24 and 48 h post-wound by measuring the remaining unmigrated area, and were expressed as the percentage to the control (B). (C) The effects of G6PD knockdown on invasion of MHCC97H and HCCLM3 cells measured by matrigel cell invasion assay. The abilities of cell invasion were quantified by counting the invaded cell number under a phase-contrast microscope, and were expressed as the percentage to the control (right of C). Representative results from at least three experiments are shown. Statistical analysis was performed with one-way ANOVA (Bonferroni post-test). *P < 0.05, ***P < 0.001.
G6PD RNAi MHCC97H cells to examine whether it could rescue the reduction of phospho-STAT3 expression, the shift of EMT status and the inhibition of cell invasion. Remarkably, overexpressed G6PD increased the expression of phospho-STAT3, Twist, E-cadherin, and N-cadherin in G6PD RNAi MHCC97H cells to almost similar levels in control RNAi MHCC97H cells (Fig. 6C) , and rescued the reduced cell invasion ability of G6PD RNAi MHCC97H cells (Fig. 6D) . Furthermore, when the phospho-STAT3 expression was suppressed by STAT3 specific inhibitor Static in G6PD re-expressed G6PD RNAi MHCC97H cells (Fig. 6C) , the rescue effect of G6PD reexpression disappeared (Fig. 6C-E) . We then performed IHC analysis and found that G6PD expression was positively correlated with phospho-STAT3 expression and N-cadherin expression in HCC tissues (Fig. 6F,G) . These results demonstrate that G6PD promotes EMT by activating STAT3 pathway in HCC cells.
EMT has frequently been observed in drug-resistant cancer cells in both preclinical models and clinical samples. So we further examined the effect of G6PD knockdown on the chemo-sensitivity of oxaliplatin in HCC cells. The results showed that knockdown of G6PD significantly enhanced the sensitivity of MHCC97H cells to oxaliplatin, and that reintroducing G6PD brought the sensitivity of G6PD RNAi MHCC97H cells to oxaliplatin to almost the same levels of control RNAi MHCC97H cells, while the rescue effect of G6PD re-expression was disappeared when the STAT3 specific inhibitor Stattic was used Statistical analysis was performed with one-way ANOVA (Bonferroni post-test). ***P < 0.001, ns, not significant. (Fig. 6H) . This result suggests that inhibition of G6PD expression may increase the chemo-sensitivity in HCC.
Discussion
Hong et al. [13] have demonstrated that G6PD expression is higher in HCC tissues, especially in those advanced-stages of HCCs, compared to normal tissues, and that higher expression of G6PD is significantly associated with worse progression-free survival and overall survival in HCC patients who received sorafenib treatment after liver cancer surgery. Our study further confirmed a close relationship between G6PD expression and HCC metastasis (Figs. 1 and 2) . Furthermore, the results of Kaplan-Meier survival curves and Cox multivariate analysis indicate that overexpression of G6PD may be an independent predictor of poor clinical outcome and decreased survival (Fig. 2) . To our knowledge, this is the report on a large number of clinical samples looking at the predictive power of G6PD expression in HCC and the correlation between G6PD expression and clinicopathologic features and prognosis of HCC patients. The Kaplan-Meier analysis by using TCGA database also showed that expression of G6PD was negatively correlated to HCC patient survival (data not shown), which is consistent with our results (Fig. 2D) .
Glucose metabolic changes are observed in many cancers including HCC [4] . However, few cases about metastasis-specific metabolic changes have been reported. Here, our study shows that the G6PD is elevated in HCC, and correlates with HCC metastasis, indicating the high activation of PPP pathway may be a hallmark in HCC metastasis. Further studies will focus on the effect of targeting this pathway on HCC metastasis in animal models.
Elevated G6PD is observed in many cancers, and is required for cancer cell growth by producing ribose-5-phosphate and NADPH. Here, we found that G6PD also contributes to HCC cell EMT and invasion. G6PD catalyzes the oxidation of glucose-6-phosphate (G6P) to 6-phosphogluconolactone and the production of reducing equivalents in the form of NADPH to meet the cellular needs for macromolecular biosynthesis and maintenance of the cellular redox status [9] . Therefore, G6PD is of unique importance to many cellular processes and enzymes that use NADPH. These processes and enzymes include antioxidant system, the family of enzymes called NADPH oxidases, lipid production and the NADPH-cytochrome P450 oxidoreductase [9] . Recent studies have shown that nitric oxide and superoxide dismutase, two important enzymes involved in antioxidant system, could promote the EMT and invasion of pancreatic cancer cells [25, 26] . NADPH oxidases have many essential physiological functions, and many of these enzymes are considered as the major source of reactive oxygen species (ROS). A previous study has associated the invasive and metastatic behaviors of tumor cells with increased levels of intracellular ROS [27] . Our results are in agreement with these observations that many enzymes affected by G6PD levels are associated with tumor invasion and metastasis.
EMT enhances malignant transformation and cancer invasiveness. The relationship between glucose metabolic alternations and EMT has not been fully determined. Dong et al. [28] reported that loss of FBP1, an enzyme in glucose metabolism, by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Another study showed that twist, the key transcription factor in EMT, promotes reprogramming of glucose metabolism in breast cancer cells [29] . The results from our studies showed that the glucose metabolic alternation, elevated G6PD expression, can regulate EMT by activation of STAT3 pathway in HCC cell lines.
Phosphorylation of the STAT3 (Y705) residue can be induced by cytokines (IL-6, IFN-α), growth factors (EGFR, HER2 and PDGFR) and non-receptor tyrosine kinases (Src and the JAK family proteins) [30] [31] [32] . In this study, we showed that knockdown of G6PD could lead to a significant reduction of the expression of phospho-STAT3 (Y705) in MHCC97H cells (Fig. 6) . The mechanism underlying how G6PD expression regulates the phosphorylation of the STAT3 in HCC is an interesting point for future study. A previous study showed that G6PD overexpression stimulated the expression of various proinflammatory cytokine genes, including IL-6, IL-1β, MCP-1, and TNF-α in macrophages in the adipose tissue of obese animals [33] . So, it will be interesting to test whether elevated G6PD expression contributes to STAT3 phosphoration by up-regulating IL-6 expression in HCC cells.
The mechanism underlying the elevated expression of G6PD in HCC is also an interesting point for future study. Several studies have reported the mechanism for up-regulating G6PD expression in cancer cells. Du et al. [34] reported that TAp73 enhances cancer cell growth through upregulating G6PD expression. Another study showed that androgen receptor up-regulated G6PD through activating mTOR in prostate cancer [35] . Hong et al. [13] found that Tcl1 increased G6PD pre-mRNA splicing and protein expression in a heterogeneous nuclear ribonucleoprotein (hnRNPK)-dependent manner, while PTEN also formed a complex with hnRNPK, which inhibited G6PD pre-mRNA splicing. Interestingly, by using TCGA database, we found that the CpG methylation level of G6PD promoter in HCC tissues is significantly lower than that in adjacent normal tissues (data not shown), suggesting that promoter hypomethylation may also be involved in the elevated expression of G6PD in HCC.
In conclusion, we found that G6PD expression is elevated in HCC, and is significantly associated with HCC metastasis and poor prognosis of HCCs. Further studies revealed that G6PD contributes to HCC migration and invasion of hepatocellular carcinoma cells by inducing EMT through activation of STAT3 pathway. Our findings suggest that targeting G6PD may open up possibilities for therapeutic intervention and improve the prognosis of patients with HCC.
